SEC Comment Letter for PDL BIOPHARMA, INC. (CIK 0000882104) — Jul 8, 2020
PDL BIOPHARMA, INC. (CIK 0000882104)
Date: July 8, 2020 · CIK: 0000882104 · Accession: 0000000000-20-006120
AI Filing Summary & Sentiment
File numbers found in text: 000-19756
Letter
United States securities and exchange commission logo July 8, 2020 Christopher Stone Vice President and General Counsel PDL BioPharma, Inc. 932 Southwood Boulevard Incline Village, Nevada 89451 Re:PDL BioPharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 5, 2020 File No. 000-19756 Dear Mr. Stone: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jacob D. Steele
Show Raw Text
United States securities and exchange commission logo
July 8, 2020
Christopher Stone
Vice President and General Counsel
PDL BioPharma, Inc.
932 Southwood Boulevard
Incline Village, Nevada 89451
Re:PDL BioPharma, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed May 5, 2020
File No. 000-19756
Dear Mr. Stone:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jacob D. Steele